Alpine Immune Sciences Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 142

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $4.9B

Alpine Immune Sciences General Information

Description

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Contact Information

Formerly Known As
N30 Pharmaceuticals, Inc, Nivalis Therapeutics, Inc
Ownership Status
Privately Held (backing)
Financing Status
Pending Transaction (M&A)
Corporate Office
  • 188 East Blaine Street
  • Suite 200
  • Seattle, WA 98102
  • United States
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 188 East Blaine Street
  • Suite 200
  • Seattle, WA 98102
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alpine Immune Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 20-Apr-2024 $4.9B Completed Generating Revenue
10. 2PO 06-Nov-2023 Completed Generating Revenue
9. 2PO 21-Sep-2022 Completed Generating Revenue
8. PIPE 14-Sep-2021 Completed Generating Revenue
7. Secondary Transaction - Open Market Completed Generating Revenue
6. PIPE 24-Jul-2020 Completed Generating Revenue
5. PIPE 18-Jan-2019 Completed Generating Revenue
4. Reverse Merger 18-Apr-2017 Completed Generating Revenue
3. Later Stage VC 01-Apr-2017 $17M $66.3M Completed Generating Revenue
2. Early Stage VC (Series A2) 13-Jun-2016 $48M $49.3M Completed Generating Revenue
To view Alpine Immune Sciences’s complete valuation and funding history, request access »

Alpine Immune Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2
Series A1
Seed 5,000,000 $0.000100 6% $0.25 $0.25 1x $0.25 17.56%
To view Alpine Immune Sciences’s complete cap table history, request access »

Alpine Immune Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein
Pharmaceuticals
Seattle, WA
142 As of 2023

Tarrytown, NY
 

Brisbane, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alpine Immune Sciences Competitors (9)

One of Alpine Immune Sciences’s 9 competitors is Regeneron Pharmaceuticals, a Formerly VC-backed company based in Tarrytown, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY
Vera Therapeutics Formerly VC-backed Brisbane, CA
Shattuck Labs Formerly VC-backed Austin, TX
Xencor Formerly VC-backed Pasadena, CA
Zymeworks Formerly VC-backed Vancouver, Canada
You’re viewing 5 of 9 competitors. Get the full list »

Alpine Immune Sciences Patents

Alpine Immune Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4490173-A1 Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses Pending 07-Mar-2022
CA-3216795-A1 Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein Pending 07-May-2021
AU-2022269139-A1 Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein Pending 07-May-2021
EP-4333869-A1 Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein Pending 07-May-2021
US-20240279310-A1 Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein Pending 07-May-2021 C07K14/70578
To view Alpine Immune Sciences’s complete patent history, request access »

Alpine Immune Sciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alpine Immune Sciences Acquisitions (1)

Alpine Immune Sciences’s most recent deal was a Merger/Acquisition with Nivalis Therapeutics for . The deal was made on 24-Jul-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nivalis Therapeutics 24-Jul-2017 Merger/Acquisition Biotechnology
To view Alpine Immune Sciences’s complete acquisitions history, request access »

Alpine Immune Sciences ESG

Risk Overview

Risk Rating

Updated January, 10, 2023

29.73 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view Alpine Immune Sciences’s complete esg history, request access »

Alpine Immune Sciences FAQs

  • When was Alpine Immune Sciences founded?

    Alpine Immune Sciences was founded in 2007.

  • Where is Alpine Immune Sciences headquartered?

    Alpine Immune Sciences is headquartered in Seattle, WA.

  • What is the size of Alpine Immune Sciences?

    Alpine Immune Sciences has 142 total employees.

  • What industry is Alpine Immune Sciences in?

    Alpine Immune Sciences’s primary industry is Pharmaceuticals.

  • Is Alpine Immune Sciences a private or public company?

    Alpine Immune Sciences is a Private company.

  • What is the current valuation of Alpine Immune Sciences?

    The current valuation of Alpine Immune Sciences is .

  • What is Alpine Immune Sciences’s current revenue?

    The current revenue for Alpine Immune Sciences is .

  • How much funding has Alpine Immune Sciences raised over time?

    Alpine Immune Sciences has raised $508M.

  • Who are Alpine Immune Sciences’s competitors?

    Regeneron Pharmaceuticals, Vera Therapeutics, Shattuck Labs, Xencor, and Zymeworks are some of the 9 competitors of Alpine Immune Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »